No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Philips Receives Grant to Improve Quality & Accessibility of Maternal Care in Low & Middle Income Countries

Editor: What To Know

  • Philips and the Philips Foundation have several ongoing programs to reduce maternal and newborn mortality in underserved communities, including a partnership with the United Nations Population Fund and the Government of Republic of the Congo and with Aga Khan University's Center of Excellence in Women and Child Health in East Africa.
  • “This effort to use AI to help deliver high quality pre-natal care to the vast number of women in the world who cannot easily access it is a perfect example of what we believe AI should be used for –.
  • It also builds on the expertise of the Philips Foundation, providing access to quality healthcare for underserved communities worldwide, including a program in Kenya to educate midwives to deliver ultrasound-based antenatal pregnancy screening in village clinics, while receiving telehealth support from radiologists at distance.

Royal Philips today announced it has received a USD 15.4 million grant from the Bill & Melinda Gates Foundation to develop an artificial intelligence (AI) based application suite to improve the quality and accessibility of obstetric care in low- and middle-income countries, especially in underserved communities.

By helping front-line healthcare workers such as midwives to identify potential problems in pregnancy at an early stage, the project aims to significantly reduce the number of women who die as a result of pregnancy – currently around 830 women every day worldwide [1] – while reducing fetal mortality and morbidity.

The project plans to develop an application suite that will be deployed on Philips Handheld Ultrasound – Lumify – which is currently in widespread use in community-based mother and child care programs around the world. It also builds on the expertise of the Philips Foundation, providing access to quality healthcare for underserved communities worldwide, including a program in Kenya to educate midwives to deliver ultrasound-based antenatal pregnancy screening in village clinics, while receiving telehealth support from radiologists at distance.

“Philips is a pioneer in the use of artificial intelligence in healthcare, with many of its AI-based solutions already FDA approved,” said Joseph Frassica, Head of Philips Research Americas and Chief Medical Officer, Philips North America. “This effort to use AI to help deliver high quality pre-natal care to the vast number of women in the world who cannot easily access it is a perfect example of what we believe AI should be used for – empowering healthcare professionals to help them deliver faster and more efficient care to help improve patient outcomes.”

Enhancing skills of midwives in low and middle-income countries

Handheld diagnostic ultrasound platforms like Philips Lumify offer an affordable solution to assess pregnancy, while providing a portable option to be used in community-based mother and child care programs. However, front-line midwives often lack the required training and ultrasound experience to make a confident diagnosis. AI-enabled applications have the potential to bridge this gap by providing assistance to acquire the right images and then assist with interpretation of those images. The suite of AI-based obstetrics applications will help front-line healthcare workers to identify high-risk pregnancies that can be clinically managed to prevent adverse birth outcomes.

AI-guided assessment of gestational age and fetal development

The World Health Organization recommends at least one ultrasound scan before 24 weeks of gestation for pregnant women to evaluate gestational age with greater confidence than a traditional last menstrual period estimate [2]. A better estimate of gestational age can reduce the number of induced labors and, as a result, help improve the birthing experience for a large number of women. Appropriate targeting of maternal and neonatal care can also help to prevent complications of prematurity. Currently, no ultrasound device is commercially available that assists non-expert users by automating image acquisition or image interpretation for a comprehensive set of obstetrics measurements, limiting access to early fetal ultrasound scans.

“Philips Handheld Ultrasound – Lumify – is a great example of how Philips is bringing diagnostic insights to the point of care to deliver on the ‘quadruple aim’ of healthcare: better health outcomes, an improved experience for patients and staff, and a lower cost of care,” said Matthijs Groot Wassink, General Manager for Access and Obstetric Ultrasound at Philips. “Supported through funding from the Bill & Melinda Gates foundation, we now have the opportunity to extend those enhanced patient and staff experiences to pregnant women and midwives throughout the world, while at the same time reducing maternal and infant mortality and morbidity, and making high quality prenatal care much more affordable in low-resource settings.”

Philips and the Philips Foundation have several ongoing programs to reduce maternal and newborn mortality in underserved communities, including a partnership with the United Nations Population Fund and the Government of Republic of the Congo and with Aga Khan University’s Center of Excellence in Women and Child Health in East Africa.

Philips is a leader in ultrasound solutions with a large global installed base and a strong track record of industry-first innovations in areas such as 3D imaging of the heart, AI-powered quantification tools, and ultra-mobile portable ultrasound solutions. Its ultrasound portfolio supports the effective and efficient delivery of care across a broad range of clinical specialties including radiology, cardiology, point-of-care and obstetrics/gynecology. Visit Philips Ultrasound Systems portfolio for more information, and join Philips at RSNA 2021 where the company will spotlight its latest portfolio of connected radiology workflow solutions and smart connected imaging systems to increase efficiency and diagnostic confidence in precision care and treatment.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy